Effectiveness of inhaled tobramycin in eradicating pseudomonas aeruginosa in children with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 13, Issue 2, 2014, Pages 172-178

  Stanojevic, Sanja ^a   Waters, Valerie ^a   Mathew, Joseph L ^a   Taylor, Louise ^a   Ratjen, Felix ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Eradication; Pediatrics; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

ANTIINFECTIVE AGENT; TOBRAMYCIN;

CHILD; CHRONIC DISEASE; COMPARATIVE STUDY; COMPLICATION; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MALE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROCEDURES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTOR; SECONDARY PREVENTION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SECONDARY PREVENTION; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 84895072308     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.09.002     Document Type: Article

References (33)

1. Li Z., Kosorok M.R., Farrell P.M., Laxova A., West S.E., Green C.G., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005, 293(5):581-588.
2. Johansen H.K., Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 1992, 47(2):109-111. [PMCID: 463585].
3. Pamukcu A., Bush A., Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995, 19(1):10-15.
4. Kosorok M.R., Zeng L., West S.E., Rock M.J., Splaingard M.L., Laxova A., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001, 32(4):277-287.
5. Henry R.L., Mellis C.M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992, 12(3):158-161.
6. Schelstraete P., Haerynck F., Van daele S., Deseyne S., De Baets F. Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa. J Cyst Fibros 2013, 12(1):1-8.
7. Littlewood J.M., Miller M.G., Ghoneim A.T., Ramsden C.H. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet 1985, 1(8433):865.
8. Steinkamp G., Tummler B., Malottke R., von der Hardt H. Treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Arch Dis Child 1989, 64(7):1022-1028. [PMCID: 1792706].
9. Rosenfeld M., Emerson J., McNamara S., Thompson V., Ramsey B.W., Morgan W., et al. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros 2012, 11(5):446-453.
10. Green D.M., McDougal K.E., Blackman S.M., Sosnay P.R., Henderson L.B., Naughton K.M., et al. Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients. Respir Res 2010, 11:140. [PMCID: 2964615].
11. Maselli J.H., Sontag M.K., Norris J.M., MacKenzie T., Wagener J.S., Accurso F.J. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr Pulmonol 2003, 35(4):257-262.
12. Mayer-Hamblett N., Kronmal R.A., Gibson R.L., Rosenfeld M., Retsch-Bogart G., Treggiari M.M., et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012, 47(2):125-134. [PMCID: 3214247].
13. Waters V., Stanojevic S., Atenafu E.G., Lu A., Yau Y., Tullis E., et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012, 40(1):61-66.
14. Wiesemann H.G., Steinkamp G., Ratjen F., Bauernfeind A., Przyklenk B., Doring G., et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998, 25(2):88-92.
15. Gibson R.L., Emerson J., McNamara S., Burns J.L., Rosenfeld M., Yunker A., et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003, 167(6):841-849.
16. Kerem E., Reisman J., Corey M., Canny G.J., Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992, 326(18):1187-1191.
17. Kuczmarski R.J., Ogden C.L., Guo S.S., Grummer-Strawn L.M., Flegal K.M., Mei Z., et al. CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2000, 2002(246):1-190.
18. Organization W.H. WHO child growth standards: methods and development 2006, [[updated 2006; cited 2013 June 18, 2013]; Available from].
19. Quanjer P.H., Stanojevic S., Cole T.J., Baur X., Hall G.L., Culver B.H., et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012, 40(6):1324-1343.
20. Waters V., Yau Y., Prasad S., Lu A., Atenafu E., Crandall I., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011, 183(5):635-640.
21. Canada C.F. Canadian Patient Data Registry report 2010, [Toronto, Canada; Contract No.: Document Number|].
22. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2(1):29-34.
23. Valerius N.H., Koch C., Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991, 338(8769):725-726.
24. Ratjen F., Doring G., Nikolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001, 358(9286):983-984.
25. Gibson R.L., Emerson J., Mayer-Hamblett N., Burns J.L., McNamara S., Accurso F.J., et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007, 42(7):610-623.
26. Proesmans M., Vermeulen F., Boulanger L., Verhaegen J., De Boeck K. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2013, 12(1):29-34.
27. Amin R., Subbarao P., Jabar A., Balkovec S., Jensen R., Kerrigan S., et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 2010, 65(5):379-383.
28. Vandyke R.D., McPhail G.L., Huang B., Fenchel M.C., Amin R.S., Carle A.C., et al. Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis. Ann Am Thorac Soc 2013, 10(3):205-212.
29. Mayer-Hamblett N., Rosenfeld M., Treggiari M.M., Konstan M.W., Retsch-Bogart G., Morgan W., et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatr Pulmonol October 2013, 48(10):943-953.
30. Frederiksen B., Koch C., Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999, 28(3):159-166.
31. Brett M.M., Simmonds E.J., Ghoneim A.T., Littlewood J.M. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Arch Dis Child 1992, 67(9):1086-1088. [PMCID: 1793633].
32. Taccetti G., Bianchini E., Cariani L., Buzzetti R., Costantini D., Trevisan F., et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax 2012, 67(10):853-859.
33. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N., Khan U., Kulich M., Kronmal R., et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011, 165(9):847-856.